Aug 05, 2016 - The following slide deck was published by Teva Pharmaceutical Industries Limited in conjunction with their 2016 Q2 earnings call.
Aug 05, 2016 - In addition to reporting better-than-expected results, Teva (TEVA) also closed the Actavis Generics deal and announced it will be acquiring Allergan's Anda business.
Aug 04, 2016 - Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)Q2 2016 Earnings CallAugust 04, 2016 8:00 am ETExecutivesKevin C. Mannix - Senior Vice President, Head of Investor RelationsErez Vigodman - President, Ch
Aug 04, 2016 - Teva Pharmaceutical ([[TEVA]] +0.6%) Q2 results: Revenues: $5,038M (+1.4%); R&D Expense: $375M (-2.8%); SG&A: $1,263M (+6.6%); Operating Income: $361M (-45
Aug 04, 2016 - Allergan's (AGN) Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is a negative 1.49% - will the stock disappoint?
Aug 04, 2016 - Teva (TEVA) completed the Actavis Generics acquisition earlier this week.
Aug 03, 2016 - Teva Pharmaceutical ([[TEVA]] +1%) CEO Erex Vigodman tells Bloomberg that the completion of its $40.5B purchase of Allergan's ([[AGN]] +1.6%) generics unit
Aug 03, 2016 - How will drug stocks like BMRN, TEVA, REGN and others, scheduled to report on Aug 4, fare this earnings season?
Aug 02, 2016 - Our proven model shows that Teva (TEVA) is likely to beat earnings this quarter because it has the right combination of two key ingredients.
Jul 27, 2016 - The U.S. Federal Trade Commission ((FTC)) accepts the proposed consent order related to Teva Pharmaceutical Industries' ([[TEVA]] +1.4%) acquisition of Act